Laurus Labs: Brokerages Bullish as CDMO Pivot Drives Growth

Laurus Labs is witnessing a significant structural transformation, shifting from a traditional drug maker to a high-value Contract Development and Manufacturing Organisation (CDMO) powerhouse. With a 30% share price surge in just two months, the company is leveraging improved margins and massive capital expenditure to redefine its long-term growth trajectory.

Strategic Shift Towards High-Value CDMO Segments

Laurus Labs is successfully executing a strategic pivot that reduces its reliance on legacy products. Six years ago, the CDMO segment contributed a mere 13% to total revenue; today, it stands at over 30%. The company aims to push this contribution to 50% by FY30.

This shift is most evident in the company’s product mix. Dependence on traditional antiretroviral (ARV) therapies has dropped significantly from 67% to approximately 41%. In FY26, the CDMO segment recorded a robust 36% year-on-year growth, reaching ₹2,080 crore. This momentum is fueled by strong outsourcing demand from global pharmaceutical players, progress in late-stage pipelines, and the increased commercialisation of novel molecules.

Margin Expansion and Operational Efficiency

A key driver behind the recent investor enthusiasm is the company's improving profitability. Laurus Labs reported a substantial expansion in its EBITDA margin (before depreciation and amortisation), which rose by 670 basis points year-on-year to reach 26.8%.

This margin improvement is largely attributed to higher operating leverage. While management expects to sustain margins at these current levels, they have noted that future trends will remain sensitive to volatility in raw material prices. Beyond core pharma, the company is also diversifying into non-pharma sectors like crop science and animal health. Currently valued at roughly ₹150 crore, Motilal Oswal Financial Services (MOFSL) expects these segments to scale beyond ₹1,000 crore in the future.

Aggressive ₹3,000-Crore Capex Roadmap

To support its ambitious growth targets, Laurus Labs has outlined a capital expenditure plan of ₹3,000 crore over the next two years. Over 90% of this investment is earmarked for expanding mid and large-scale manufacturing capacities.

Key highlights of this expansion include:

  • Greenfield Unit 7: A facility featuring over 2,000 cubic meters of reactor capacity.
  • Commercial Block: A second commercial block slated for validation by the September 2026 quarter.
  • Diversification Projects: Targeted investments in fermentation, peptides, advanced therapies, and animal health formulation facilities.

Analyst Outlook and Earnings Projections

The combination of capacity expansion and CDMO traction has led brokerages to remain optimistic. Motilal Oswal Financial Services has maintained a 'BUY' rating, raising its earnings estimates for FY27 by 8% and for FY28 by 6%. Analysts expect the CDMO segment to maintain a steady annual growth rate of 22% throughout the FY26-28 period, backed by both development projects and commercialised molecules.

Key Takeaways

  • CDMO Dominance: The CDMO segment is projected to grow from its current 30% revenue contribution to 50% by FY30.
  • Robust Capex: A ₹3,000-crore investment plan over the next two years focuses on expanding manufacturing capacities and entering advanced therapies.
  • Margin Growth: Improved operating leverage has driven EBITDA margins up by 670 basis points to 26.8% in FY26.